Find a company by name or ticker and open its page
We use analytics cookies to understand how you use Stockoscope and improve the platform. Essential cookies that keep you logged in are always on. Cookie policy
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.
Read full article
Xeris Biopharma (NASDAQ: XERS - Get Free Report) and Corcept Therapeutics (NASDAQ: CORT - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Institutional and Insider Ownership 42.7% of Xeris Biopharma
Read full article
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris' Board of Directors granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of its common stock to 60 new employees under Xeris' Inducement Equity Plan.
Read full article
Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) traded up 5.2% during mid-day trading on Monday. The company traded as high as $9.38 and last traded at $9.5750. Approximately 460,484 shares changed hands during trading, a decline of 75% from the average daily volume of 1,858,300 shares. The stock had previously closed at $9.10.
Read full article
Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported on Tuesday, citing people familiar with the matter.
Read full article
Shares of Xeris Biopharma Holdings, Inc. (NASDAQ: XERS - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy
Read full article